Forest: tough road filling patent loss, as 4Q profit tumbles 40% on Lexapro generics
This article was originally published in Scrip
Executive Summary
Forest Laboratories' fiscal fourth-quarter earnings fell 40% as the firm had to face its first quarter without US patent protection for its best-seller Lexapro (escitalopram oxalate).